Tradestie Institutional Equity Comparison Engine

FBL vs ABOS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABOS Overall Edge

ABOS Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acumen Pharmaceuticals, Inc. Common Stock (ABOS) driven by superior Growth & Margin, Options & Structure while FBL counters with relative strength in Momentum & Technical. Fundamentally, FBL trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ABOS at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, FBL sits in UNCLASSIFIED (36th %ile IV; Dealer Gamma Walls on Pro) against ABOS sits in UNCLASSIFIED (41st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
FBL N/M vs ABOS N/M Fwd P/E
Growth & Margin Winner ABOS
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner FBL
1Y -20.8% vs -88.7% ยท 52W Pos 24% vs 0%
Options & Structure Winner ABOS
UNCLASSIFIED (36th %ile IV) vs UNCLASSIFIED (41st %ile IV)
FBL NASDAQ
GraniteShares ETF Trust GraniteShares 2x Long META Daily ETF
Institutional Equity
$22.88
-5.22% 1D
Market Cap N/A
1M Return -23.99%
1Y Return -20.78%
Forward P/E N/M
Unified AI Score
56.6 / 100 HOLD
Tech 65.0 Fund 58.0 Flow 50.0 Mom 50.0
ABOS NASDAQ
Acumen Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.21
-4.04% 1D
Market Cap $15.8M
1M Return -87.85%
1Y Return -88.65%
Forward P/E N/M
Unified AI Score
57.4 / 100 HOLD
Tech 76.0 Fund 62.0 Flow 68.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FBL -20.78% ABOS -88.65% Spread: +67.87 pp (FBL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
FBL TTM Op. Margin: N/A ABOS TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FBL vs ABOS. Trailing 12-month operating profitability (FBL N/A vs ABOS 0.0%) and valuation multiples (FBL N/M vs ABOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FBL (2) vs ABOS (6)
Institutional Metric FBL ABOS Criterion Row Winner
Market Capitalization Scale N/A $15.8M Larger Scale ABOS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth ABOS
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin ABOS
Net Profit Margin Profitability N/A 0.0% Higher Margin ABOS
Return on Equity (ROE) Capital Efficiency N/A -162.7% Higher ROE ABOS
52-Week Range Position Momentum 24% ($17โ€“$40) 0% ($0โ€“$4) Stronger Trend FBL
Beta / 30D Volatility Risk Regime 2.86ฮฒ ยท 82% Vol 2.67ฮฒ ยท 335% Vol Lower Realized Risk FBL
Unified Institutional Score Composite Signal 56.6 / 100 (HOLD) 57.4 / 100 (HOLD) Higher Composite ABOS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FBL vs ABOS Buy Guide
FBL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live FBL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABOS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 41st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ABOS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FBL nor ABOS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.